PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Budesonide - Oesophagitis (maintenance)
PAD Profile : Budesonide - Oesophagitis (maintenance)
Keywords :
eosinophilic oesophagitis, esophagitis, budesonide orodispersible, EOS, EoE
Brand Names Include :
Jorveza
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
- Inflammatory bowel disease
- Oesophagitis (inducing remission)
- Covid-19
- Nephropathy
- Asthma
- Bronchopulmonary dysplasia
Additional Documents
Type
Document
Review Date
Shared Care
01 November 2024
Committee Recommendations
Date
Committee Name
Narrative
03 November 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed the use of budesonide for maintenance of Eosinophilic Oesophagitis at the lowest effective dose.
Prescribing will be initiated by the specialist and continue for an initial 3 months before a request is made to the primary care clinician.
A BLUE information sheet for prescribers can be found below.
Associated BNF Codes
01. Gastro-Intestinal System
01.05.02. Corticosteroids